| Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers (NCT02668367) | Biota Pharmaceuticals, Inc. | 2015-11-01 |
| Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects (NCT02506257) | SIFI SpA | 2015-11-01 |
| Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 in Lumbar Radiculopathy (Sciatica) (NCT02644421) | Brigham and Women's Hospital | 2015-11-01 |
| Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis (NCT02330653) | Stacy A. Kahn | 2015-11-01 |
| Alpha Lipoic Acid in Geographic Atrophy (NCT02613572) | University of Pennsylvania | 2015-11-01 |
| Study of Evaluation of Cavir Tab. 0.5mg With Food Effect on Pharmacokinetics and Safety (NCT02586363) | Seoul St. Mary's Hospital | 2015-11-01 |
| Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck (NCT02474368) | Dana-Farber Cancer Institute | 2015-11-01 |
| Lorcaserin Intra Venous Cocaine Effects (NCT02680288) | Midwest Biomedical Research | 2015-11-01 |
| Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD (NCT02599064) | RXi Pharmaceuticals, Corp. | 2015-11-01 |
| A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body (NCT02538874) | Bristol-Myers Squibb | 2015-10-31 |
| Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers (NCT02594189) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-31 |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma (NCT02572167) | Seagen Inc. | 2015-10-31 |
| A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (NCT02568397) | AstraZeneca | 2015-10-31 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas (NCT02323880) | Children's Oncology Group | 2015-10-30 |
| FDA Approved Medication to Reduce Binge Eating and/or Purging (NCT02553824) | Stanford University | 2015-10-30 |
| Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol (NCT02533427) | Gilead Sciences | 2015-10-29 |
| Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease (NCT02234934) | University of California, Los Angeles | 2015-10-29 |
| The Safety and Pharmacokinetics of Primapur and Gonal-f (NCT03857230) | IVFarma LLC | 2015-10-29 |
| Oral Bio-equivalence Study (NCT05145621) | Alembic Pharmaceuticals Ltd. | 2015-10-29 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance (NCT02593331) | Genentech, Inc. | 2015-10-29 |
| A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors (NCT02571569) | Bayer | 2015-10-28 |
| A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. (NCT02579226) | AstraZeneca | 2015-10-28 |
| Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector (NCT02606903) | Boehringer Ingelheim | 2015-10-28 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma (NCT02481310) | Northwestern University | 2015-10-28 |
| A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (NCT02608125) | Principia Biopharma, a Sanofi Company | 2015-10-28 |
| Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies (NCT02473224) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-28 |
| A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles (NCT02594033) | Novo Nordisk A/S | 2015-10-27 |
| Skin Irritation Study of GSK2894512 Cream (NCT02637206) | GlaxoSmithKline | 2015-10-27 |
| KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis (NCT05522816) | PharmaEssentia | 2015-10-27 |
| Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (NCT01955980) | Pari Pharma GmbH | 2015-10-27 |
| A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) (NCT02493751) | Pfizer | 2015-10-26 |
| Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC (NCT02585973) | UNC Lineberger Comprehensive Cancer Center | 2015-10-26 |
| Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD (NCT02578030) | Shire | 2015-10-24 |
| A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215 (NCT02571816) | Astellas Pharma Global Development, Inc. | 2015-10-23 |
| Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011 (NCT02431481) | Novartis Pharmaceuticals | 2015-10-23 |
| Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod (NCT03757338) | Asofarma S.A.I. y C. | 2015-10-23 |
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors (NCT02422589) | Novartis Pharmaceuticals | 2015-10-23 |
| Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects (NCT02508376) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-22 |
| A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors (NCT02563548) | Halozyme Therapeutics | 2015-10-22 |
| A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors (NCT02561234) | Immedica Pharma AB | 2015-10-22 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects (NCT02587520) | Sanofi Pasteur, a Sanofi Company | 2015-10-22 |
| A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (NCT02519452) | Janssen Research & Development, LLC | 2015-10-22 |
| Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (NCT02381535) | National Cancer Institute (NCI) | 2015-10-22 |
| Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis (NCT02548052) | GlaxoSmithKline | 2015-10-22 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861) | National Cancer Institute (NCI) | 2015-10-21 |
| A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (NCT02596503) | University of Colorado, Denver | 2015-10-21 |
| Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study (NCT02265874) | Ohio State University | 2015-10-21 |
| Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults (NCT02547792) | Vaxart | 2015-10-20 |
| Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De) (NCT02620332) | King's College London | 2015-10-20 |
| Effects of RLIC on Motor Learning in Middle-aged and Older Adults (NCT03582943) | Washington University School of Medicine | 2015-10-20 |
| A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers (NCT05674669) | Eleusis Therapeutics | 2015-10-20 |
| A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects (NCT02576119) | ViiV Healthcare | 2015-10-19 |
| Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients (NCT02426723) | JW Pharmaceutical | 2015-10-19 |
| [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001) (NCT02562989) | Merck Sharp & Dohme LLC | 2015-10-19 |
| A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants (NCT05873907) | Amgen | 2015-10-19 |
| A Study of Galcanezumab in Healthy Participants (NCT02576951) | Eli Lilly and Company | 2015-10-19 |
| Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency (NCT02199496) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-19 |
| Hematopoietic Stem Cell Transplant for Sickle Cell Disease (NCT02065596) | Case Comprehensive Cancer Center | 2015-10-19 |
| A Phase I Study of TS-142 in Healthy Participants (Single Doses) (NCT04169893) | Taisho Pharmaceutical Co., Ltd. | 2015-10-17 |
| A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (NCT02516527) | Bristol-Myers Squibb | 2015-10-16 |
| Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (NCT02537418) | Canadian Cancer Trials Group | 2015-10-16 |
| A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1 (NCT02572388) | University of Oxford | 2015-10-15 |
| CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients (NCT03252171) | Fuda Cancer Hospital, Guangzhou | 2015-10-15 |
| MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma (NCT02551055) | Millennium Pharmaceuticals, Inc. | 2015-10-15 |
| A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously (NCT02618512) | Alexion Pharmaceuticals, Inc. | 2015-10-15 |
| An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. (NCT02598960) | Bristol-Myers Squibb | 2015-10-14 |
| Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer (NCT02476539) | Tianjin Hemay Pharmaceutical Co., Ltd | 2015-10-14 |
| A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (NCT02558816) | Nantes University Hospital | 2015-10-14 |
| Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy (NCT02446704) | Zofia Piotrowska | 2015-10-13 |
| Use of High Resolution Colonic Manometry in Studying Motility (NCT02574611) | James J. Peters Veterans Affairs Medical Center | 2015-10-13 |
| Intraspinal Transplantation of Autologous ADRC in ALS Patients (NCT03296501) | Mossakowski Medical Research Centre Polish Academy of Sciences | 2015-10-13 |
| An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (NCT02488759) | Bristol-Myers Squibb | 2015-10-13 |
| Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058 (NCT04991194) | Bial - Portela C S.A. | 2015-10-12 |
| Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer (NCT02562898) | Margaret Tempero | 2015-10-12 |
| A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313 (NCT02532049) | University of Oxford | 2015-10-12 |
| DDI (Effect of Metformin and Furosemide on Rosuvastatin PK) (NCT02574845) | Boehringer Ingelheim | 2015-10-12 |
| Bright Light on Fatigue in Women Being Treated for Breast Cancer (NCT02658708) | Washington University School of Medicine | 2015-10-12 |
| The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor (NCT03641586) | BeiGene | 2015-10-12 |
| A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02558140) | Hoffmann-La Roche | 2015-10-11 |
| Study of Intradermal Injections of RCS-01 in Male and Female Subjects (NCT02391935) | RepliCel Life Sciences, Inc. | 2015-10-10 |
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT02477215) | Parameswaran Hari | 2015-10-09 |
| Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) (NCT03785652) | Luye Pharma Group Ltd. | 2015-10-09 |
| Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery (NCT02538510) | University of Washington | 2015-10-08 |
| Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients (NCT02530905) | Sarepta Therapeutics, Inc. | 2015-10-08 |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (NCT02298348) | New Approaches to Neuroblastoma Therapy Consortium | 2015-10-08 |
| A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (NCT02524782) | MedImmune LLC | 2015-10-07 |
| Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia (NCT02573363) | University of Chicago | 2015-10-07 |
| Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (NCT02568280) | Novo Nordisk A/S | 2015-10-06 |
| Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (NCT02564367) | AIO-Studien-gGmbH | 2015-10-06 |
| Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers (NCT02557594) | Dong-A ST Co., Ltd. | 2015-10-06 |
| A Study of SAR428926 in Patients With Advanced Solid Tumors (NCT02575781) | Sanofi | 2015-10-05 |
| Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (NCT02420613) | M.D. Anderson Cancer Center | 2015-10-05 |
| Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer (NCT02312661) | University Medical Center Groningen | 2015-10-05 |
| A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects (NCT02568306) | Novo Nordisk A/S | 2015-10-05 |
| Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy (NCT02514447) | G1 Therapeutics, Inc. | 2015-10-05 |
| The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (NCT02250014) | University of Colorado, Denver | 2015-10-05 |
| Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors (NCT02389309) | M.D. Anderson Cancer Center | 2015-10-05 |
| Evaluation of Intranasal Naltrexone and Naloxone (NCT03851731) | National Institute on Drug Abuse (NIDA) | 2015-10-05 |
| Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (NCT02432235) | ADC Therapeutics S.A. | 2015-10-05 |
| LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (NCT03090659) | Nanjing Legend Biotech Co. | 2015-10-02 |